SCHEMBL2014488

SCHEMBL2014488

CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C(C=O)C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)O)O1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 6/20 0.55
▸ PGR P06401 5/20 0.55
▸ CYP3A4 P08684 8/20 0.50
▸ HIF1A Q16665 5/20 0.50
▸ ABCB11 O95342 3/20 0.50
▸ AR P10275 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ LMNA P02545 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ CYP17A1 P05093 1/20 0.42
▸ ABCC3 O15438 1/20 0.41
▸ ABCC4 O15439 1/20 0.41
▸ IL5 P05113 1/20 0.41
▸ NR3C2 P08235 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019946 0.85 HIF1A (0.61) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL2017730 0.84 NR3C1 (0.59) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL13654491 0.82 NR3C1 (0.54) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL11880147 0.80 HIF1A (0.62) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL2077302 0.79 HIF1A (0.62) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL13147969 0.79 HIF1A (0.62) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL2077874 0.79 HIF1A (0.62) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL2020622 0.78 HIF1A (0.73) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL13768969 0.78 HIF1A (0.64) NR3C1PGRCYP3A4HIF1AABCB11
SCHEMBL13177824 0.78 NR3C1 (0.85) NR3C1PGRCYP3A4HIF1AABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160167-A1 Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists ASTRAZENECA AB (SE) 2011-06-30 — — US disclosed
US-20110160167-A1 Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists ASTRAZENECA AB (SE) 2011-06-30 — — US disclosed
US-20110160167-A1 Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists ASTRAZENECA AB (SE) 2011-06-30 — — US disclosed
WO-2009082342-A1 STEROID DERIVATIVES ACTING AS GLUCOCORTICOSTEROID RECEPTOR AGONISTS ASTRAZENECA AB (SE) 2009-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160167-A1 Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists NR3C1, NR3C2, MC2R NR3C1 1/4885PGR 24/4885CYP3A4 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback